NVCR
NovoCure LimitedNASDAQHealthcare$10.55-2.68%ClosedMarket Cap: $1.20B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.45
P/S
1.83
EV/EBITDA
-10.58
DCF Value
$-36.19
FCF Yield
-6.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
74.5%
Operating Margin
-23.5%
Net Margin
-20.8%
ROE
-39.1%
ROA
-16.9%
ROIC
-25.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $174.3M | 75.8% | $-40.4M | $-24.5M | $-0.22 | — |
| FY 2025 | $655.4M | 74.5% | $-153.8M | $-136.2M | $-1.22 | — |
| Q3 2025 | $167.2M | 73.2% | $-36.0M | $-37.3M | $-0.33 | — |
| Q2 2025 | $158.8M | 73.9% | $-39.5M | $-40.1M | $-0.36 | — |
| Q1 2025 | $155.0M | 75.1% | $-37.9M | $-34.3M | $-0.31 | — |
| Q4 2024 | $161.3M | 79.2% | $-63.3M | $-65.9M | $-0.61 | — |
| FY 2024 | $605.2M | 77.3% | $-170.5M | $-168.6M | $-1.56 | — |
| Q3 2024 | $155.1M | 77.2% | $-32.1M | $-30.6M | $-0.28 | — |
| Q2 2024 | $150.4M | 77.0% | $-33.6M | $-33.4M | $-0.31 | — |
| Q1 2024 | $138.5M | 75.7% | $-41.5M | $-38.8M | $-0.36 | — |
| Q4 2023 | $133.8M | 75.7% | $-51.7M | $-47.1M | $-0.44 | — |
| FY 2023 | $509.3M | 74.8% | $-232.9M | $-207.0M | $-1.95 | — |